Peptide Initiative

Peptides · Peptide comparison

Livagen vs Ovagen

Tetrapeptide bioregulator (Lys-Glu-Asp-Ala) that directly penetrates cell nuclei and binds double-stranded DNA to induce chromatin decondensation in senescent lymphocytes, activate ribosomal genes, inhibit enkephalin-degrading enzymes with an IC50 of 20 μM, and restore protein synthesis capacity in aging cells through selective epigenetic remodeling

Hepatoprotective tripeptide bioregulator (Glu-Asp-Leu) that penetrates hepatocyte nuclei to bind DNA in the minor groove at AT-rich promoter regions, upregulates antioxidant enzymes (SOD, glutathione peroxidase, GST) beyond melatonin's capacity, and supports liver regeneration through epigenetic activation of hepatocyte proliferation and anti-fibrotic gene programs

  • Anti-Aging
  • Anti-Aging

At a glance

Quick comparison

Dose rangeLivagen5–10 mgOvagen10–10 mg
FrequencyLivagenOnce dailyOvagenMultiple times daily
AdministrationLivagenIntramuscular injectionOvagenOral (capsule — standard formulation)
Cycle lengthLivagen8-12 weeksOvagen8-12 weeks
Onset speedLivagenGradual (3-4 weeks)OvagenGradual (3-4 weeks)
Evidence levelLivagenLimited human trialsOvagenLimited human trials

Efficacy

Benefit ratings

Cell Renewal

Livagen94%
OvagenNo recorded rating

Liver Support

Livagen88%
OvagenNo recorded rating

DNA Protection

Livagen85%
OvagenNo recorded rating

Anti-Aging

LivagenNo recorded rating
Ovagen8%

Healing & Recovery

LivagenNo recorded rating
Ovagen8%

Metabolic

LivagenNo recorded rating
Ovagen7%

Technical data

Compound specifications

Livagen

Molecular formula
C18H31N5O9
Molecular weight
461.5 g/mol
Half-life
Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic chromatin remodeling modifications; metabolized to constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
Bioavailability
Resistant to intestinal proteolysis when administered orally (weakly hydrolyzed by intestinal peptidases); efficient absorption from intramuscular injection sites; penetrates cytoplasmic and nuclear membranes to reach cell nuclei and nucleoli
CAS number
Not assigned (research compound)

Ovagen

Molecular formula
C15H25N3O8
Molecular weight
375.4 g/mol
Half-life
Short plasma half-life typical of tripeptides; biological effects persist for weeks through epigenetic modifications to hepatic gene expression; metabolized to constituent amino acids (glutamic acid, aspartic acid, leucine)
Bioavailability
Effective via oral capsule (10 mg twice daily), sublingual liquid (0.1 mg/mL), and subcutaneous injection routes; penetrates cell membranes and nuclear membranes as a cell-penetrating peptide; tissue-specific activity demonstrated in organotypic hepatic cultures at 10⁻⁶ to 10⁻⁹ M
CAS number
Not assigned (proprietary Khavinson peptide)

Protocols

Dosing compared

Livagen

Intramuscular

  • 5-10 mgOnce daily · 10-day course (50-100 mg total)Reflects the Khavinson-laboratory bioregulator course used in practice: a total of 50-100 mg of the KEDA tetrapeptide delivered over 10 days. Livagen has no standardized human clinical dosing; evidence is largely preclinical [6].

Ovagen

Oral

  • 10 mg (1 capsule) twice dailyTwice daily with meals · 10-20 day course, repeatable after 3-6 monthsDocumented bioregulator practice dose for the EDL liver/GI peptide [2]. No controlled human trials; data are preclinical and cell-based.

Applications

Best suited for

Livagen

Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
Livagen is particularly well-suited for individuals focused on comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting liver function and hepatoprotection in the context of aging
Livagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in the context of aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Restoring protein synthesis and ribosomal function in elderly individuals
Livagen is particularly well-suited for individuals focused on restoring protein synthesis and ribosomal function in elderly individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Khavinson bioregulator protocols for anti-aging and longevity
Livagen is particularly well-suited for individuals focused on khavinson bioregulator protocols for anti-aging and longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Ovagen

Supporting liver function and hepatoprotection in aging individuals
Ovagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols targeting hepatic aging and metabolic health
Ovagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting hepatic aging and metabolic health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Recovery support after hepatic injury or liver disease
Ovagen is particularly well-suited for individuals focused on recovery support after hepatic injury or liver disease. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy for maintaining liver regenerative capacity during aging
Ovagen is particularly well-suited for individuals focused on geroprotective therapy for maintaining liver regenerative capacity during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Livagen

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Digestive enzyme changes

Uncommon

  • Transient flu-like symptoms

Serious

  • No documented serious adverse effects

Ovagen

Common

  • Mild digestive discomfort
  • Mild fatigue
  • Mild headache
  • Minor appetite changes

Uncommon

  • Mild nausea

Serious

  • No documented serious adverse effects

Research status

Safety & evidence

Livagen

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active autoimmune conditions in flare without physician supervision
  • Concurrent use of opioid medications — Livagen's enkephalinase inhibition may alter opioid metabolism

Ovagen

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Ovagen demonstrates favorable safety in reproductive endocrinology applications with no serious adverse events reported in clinical ovulation induction studies. As a kisspeptin analog, primary safety consideration is ovarian hyperstimulation syndrome (OHSS) risk, requiring careful hormone monitoring and patient education on abdominal pain, bloating, and nausea symptoms. Mild headaches and injection site reactions occur in <10% of users. Reproductive safety in animal models shows normal fetal development with no teratogenicity.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, leucine)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Severe glutamic acid metabolism disorders (extremely rare)
  • Active autoimmune hepatitis in flare without physician supervision

Decision guide

Which is right for you?

Livagen

Choose Livagen if…

  • Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
  • Supporting liver function and hepatoprotection in the context of aging
  • Restoring protein synthesis and ribosomal function in elderly individuals
  • Khavinson bioregulator protocols for anti-aging and longevity

Ovagen

Choose Ovagen if…

  • Supporting liver function and hepatoprotection in aging individuals
  • Comprehensive Khavinson bioregulator protocols targeting hepatic aging and metabolic health
  • Recovery support after hepatic injury or liver disease
  • Geroprotective therapy for maintaining liver regenerative capacity during aging